Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?

References

• Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N. Engl. J. Med.360(6), 626–633 (2009).
   PubMed Web of Science ®Google Scholar
• Drummond MF, Mason AR. European perspective on the costs and cost–effectiveness of cancer therapies. J. Clin. Oncol.25(2), 191–195 (2007).
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J. Clin. Oncol.25(2), 180–186 (2007).
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat. Clin. Pract. Oncol.4(11), 643–656 (2007).
   PubMedGoogle Scholar
• Berenson A. Cancer drugs offer hope, but at huge expense. New York Times July 12 2005.
   Google Scholar
• Gardiner H. The evidence gap: British balance benefit vs. cost of latest drugs. New York Times December 2 2008.
   Google Scholar
• Malin JL. Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society’s willingness to pay? J. Clin. Oncol.28(20), 3212–3214 (2010).
   PubMed Web of Science ®Google Scholar
• McCabe C, Bergmann L, Bosanquet N et al. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann. Oncol.20(3), 403–412 (2009).
   PubMed Web of Science ®Google Scholar
• Mason AR, Drummond MF. Public funding of new cancer drugs: is NICE getting nastier? Eur. J. Cancer45(7), 1188–1192 (2009).
   PubMed Web of Science ®Google Scholar
• Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health11(4), 771–783 (2007).
   PubMed Web of Science ®Google Scholar
• Cairns J. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy76(2), 134–143 (2006).
   PubMed Web of Science ®Google Scholar
• Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med. J. Aust.188(1), 26–28 (2008).
   PubMed Web of Science ®Google Scholar
• Chim L, Kelly PJ, Salkeld G, Stockler MR. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics28(6), 463–475 (2010).
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Torrance G, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
   Google Scholar
• Greenberg D, Rosen A, Neumann PJ. Is it cost-effective? It depends on whom you ask. Presented at: The HTAi 7th Annual Meeting. Dublin, Ireland, 6–9 June, 2010.
   Google Scholar
• McDonough CM, Tosteson AN. Measuring preferences for cost–utility analysis: how choice of method may influence decision-making. Pharmacoeconomics25(2), 93–106 (2007).
   PubMed Web of Science ®Google Scholar
• Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost–effectiveness analysis? Health Econ.13(5), 429–436 (2004).
   PubMed Web of Science ®Google Scholar
• Tengs TO. Cost–effectiveness versus cost–utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health7(1), 70–78 (2004).
   PubMed Web of Science ®Google Scholar
• Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost–utility analyses in oncology. J. Natl Cancer Inst.102(2), 82–88 (2010).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost–utility literature, 1976–2001. Value Health8(1), 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Stone PW, Schackman BR, Neukermans CP et al. A synthesis of cost–utility analysis literature in infectious disease. Lancet Infect. Dis.5(6), 383–391 (2005).
   PubMed Web of Science ®Google Scholar
• Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ. When is critical care medicine cost-effective? A systematic review of the cost–effectiveness literature. Crit. Care Med.34(11), 2738–2747 (2006).
   PubMed Web of Science ®Google Scholar
• Otero HJ, Rybicki FJ, Greenberg D, Neumann PJ. Twenty years of cost–effectiveness analysis in medical imaging: are we improving? Radiology249(3), 917–925 (2008).
   PubMed Web of Science ®Google Scholar
• Otero HJ, Rybicki FJ, Greenberg D, Mitsouras D, Mendoza JA, Neumann PJ. Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money? Int. J. Cardiovasc. Imaging26(6), 605–612 (2010).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost–utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics27(10), 861–872 (2009).
   PubMed Web of Science ®Google Scholar
• Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur. J. Cancer44(7), 972–977 (2008).
   PubMed Web of Science ®Google Scholar
• Tappenden P, Jones R, Paisley S, Carroll C. The cost–effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur. J. Cancer43(17), 2487–2494 (2007).
   PubMed Web of Science ®Google Scholar
• Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest.27(10), 953–959 (2009).
   PubMed Web of Science ®Google Scholar
• Raftery J. NICE and the challenge of cancer drugs. BMJ338, b67 (2009).
   Google Scholar
• Mayor S. NICE recommends kidney cancer drug it previously rejected on cost grounds. BMJ338, b499 (2009).
   Google Scholar
• O’Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS. Br. Med. J.337, a1262 (2008).
   PubMedGoogle Scholar
• Caro JJ, Nord E, Siebert U et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ.19(10), 1117–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Affairs28(5), (2009).
   Google Scholar
• Sculpher M, Claxton K. Sins of omission and obfuscation: IQWiG’s guidelines on economic evaluation methods. Health Econ.19(10), 1132–1136 (2010).
   PubMed Web of Science ®Google Scholar
• The Patient Protection and Affordable Care Act. PL 111–148 (2010).
   Google Scholar